Anogenital warts: a new way of solving the common problem of urology (results of long-term follow-up)
Protasov, A.D.; Lipatov, I.S.; Kostinov, M.P.; Tezikov, Y.V.; Shmitko, A.D.; Pakhomov, D.V.; Blagovidov, D.A.; Zhestkov, A.V.; Ryzhov, A.A.; Vekhova, E.V.
Urologiia 5: 47-51
2016
ISSN/ISBN: 1728-2985 PMID: 28248020 Document Number: 688005
To evaluate the effectiveness of combined use of the imiquimod 5% cream and vaccination against human papillomavirus (HPV) using a quadrivalent recombinant vaccine to achieve long-term clinical remission of chronic HPV infection manifested by anogenital warts. The study comprised 36 patients, including 22 men, aged 26.4+/-4.1 years, who had from 1 to 5 anogenital warts. Participants of the study were vaccinated by quadrivalent recombinant vaccine under a 3-dose scheme 0-2-6 months co-administered with imiquimod 5% cream three times per week up to 16 weeks. The follow-up period was 2 years. Complete disappearance of genital warts within 1 year from baseline was observed in 34 (94.4%) patients. Two patients with anogenital warts after 1 year were treated for 1 year 3 months and 1 year and 4 months with Solcoderm which lead to the complete disappearance of genital warts. There were no recurrences of genital warts during the 2 years of follow-up. Vaccination with a recombinant quadrivalent vaccine concurrently with using imiquimod 5% cream results in prolonged clinical remission of chronic HPV infection manifested by anogenital warts in at least 94.4% of the cases (2 year follow-up).